Name: CORBUS PHARMACEUTICALS HOLDI (CRBP) Stock
Brand: CORBUS PHARMACEUTICALS HOLDI
Rating: 3.5 (3 reviews)

CRBP Latest News, Press Relases and Analysis

All

Press Releases

25 days ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

a month ago - By: Benzinga - Mentions: BFLY ILMN PACB INTS ...

12 Health Care Stocks Moving In Friday's Intraday Session

a month ago - By: Benzinga - Mentions: ZJYL BENF AMZN MSAI ...

Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket

a month ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces Pricing of Public Offering

a month ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces Proposed Public Offering

2 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

2 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

3 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025

3 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

4 months ago - By: Zacks Investment Research - Mentions: CGC TLRY HRMY

Can Cannabis Stocks Reverse Their Prolonged Downtrend?

4 months ago - By: The Motley Fool

Corbus (CRBP) Q2 Loss Beats Estimates

4 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

5 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

6 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab